Results 11 to 20 of about 101 (70)
Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications. [PDF]
J Diabetes InvestigABSTRACT Type 1 diabetes is defined by immune‐mediated beta‐cell failure and dependence on exogenous insulin. That definition is correct, but it may not fully describe many people seen in current clinical practice. Overweight and obesity are now common in type 1 diabetes, leading to variable combinations of high insulin requirement, hypertension ...
Bloomgarden Z.
europepmc +2 more sources
DATTs: A Database of Disease-Associated Therapeutic Targets With Required Actions for Treatment. [PDF]
Mol InformDATTs is a new database of therapeutic protein targets. The available information includes disease–target protein associations and the actions of drugs on these proteins required for therapeutic effects (e.g., activation, inhibition, or target). DATTs currently includes information on 613 diseases, 1475 target proteins, and 7415 disease–protein ...
Sawada R +7 more
europepmc +2 more sources
Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. [PDF]
Diabetes Obes MetabABSTRACT Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.
Alhazmi A, le Roux CW.
europepmc +2 more sources
Positioning Incretin-Based and Next-Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta-Analyses. [PDF]
Diabetes Obes MetabABSTRACT Background The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin‐based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical ...
Monami M, Ragghianti B, Mannucci E.
europepmc +2 more sources
Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide. [PDF]
Diabetes Obes MetabABSTRACT Aims Zenagamtide is a novel, unimolecular glucagon‐like peptide‐1 and amylin receptor agonist in development for weight management and Type 2 diabetes. This study investigated the pharmacokinetic (PK) properties, safety and tolerability of zenagamtide in participants with various degrees of renal impairment versus participants with normal ...
Oldenburg LIK +6 more
europepmc +2 more sources
Metabolic and appetitive regulation of adipocyte mass during treatment of obesity. [PDF]
J Intern MedAbstract Adipose mass is homeostatically maintained within a narrow range despite fluctuations in daily calorie intake and activity levels. Constituting an adipose mass “set point,” this homeostatic regulation includes sensing mechanisms in the form of hormones reflecting caloric intake that serve as mediators of appetitive behaviors and adipose mass ...
Purnell JQ, Le Roux CW.
europepmc +2 more sources
Treat to target in weight management with semaglutide: Real-world evidence from an eHealth clinic. [PDF]
Diabetes Obes MetabAbstract Aims To evaluate the effectiveness of an online multidisciplinary weight loss service combining individualised semaglutide dosing with intensive behavioural therapy (IBT) in adults living with overweight or obesity. Materials and methods This retrospective cohort study included data from Danish participants enrolled in a digital weight loss ...
Seier S +4 more
europepmc +2 more sources
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
British Journal of Pharmacology, EarlyView.Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley +1 more source
Amylin analogues as a novel perspective in anti‐obesity therapy
British Journal of Pharmacology, EarlyView.Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Incretin‐based pharmacotherapy was initially developed to improve glucose‐dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next‐generation polyagonist development.
Ferenc Sztanek +3 more
wiley +1 more source